1 	|BT| (S (NP (NP (DT The) (JJ dysplastic) (NN epithelium) (NN K-rasVal12)) (CC x) (NP (NN TAgWt) (NN mouse))) (VP (VBP develop) (NP (NN neoplasm)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 62:A10.272|ES| 19:1 52:1 173:1 648:1 691:1 1523:1 5406:1 5407:1 5531:1 5532:1
1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
1 	|BT| (NP (NP (NP (DT The) (JJ H-ras) (NN codon) (CD 61) (NN mutation) (NN frequency) (JJ tetrachloroethylene-induced) (NN tumor)) (NP (NP (ADJP (RB significantly) (JJR lower) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (JJ combined) (NN control)) (NP (RB also) (CD two) (NN chemical))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 179:D01.248.497.300.459.700 194:G05.355.044.250.750 335:D13.444.735.544.355 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 34:1 117:1 124:1 164:1 289:1 369:1 691:1 933:1 1119:1 1247:1 2124:1 4338:1 5475:1 5533:1 5534:1
1 	|BT| (NP (NP (DT The) (JJ K-rasVal12-augmented) (NN apoptosis) (JJ unrelated) (NN dysplasia)) (: ;) (S (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN cycling) (JJ nondysplastic) (NNS enterocytes)) (VP (VBP produce) (NP (NN K-rasVal12) (NN TAg) (JJ COOH-terminal) (NN truncation)))))))) |ET| |BS|39:G04.299.139.160 1475:A03.556.124.369.290|ES| 5:1 19:1 89:1 203:1 217:1 261:1 385:1 691:1 1565:1 5362:1 5406:1 5508:1 5535:1 5536:1 5537:1 5538:1 5539:1 5540:1
1 	|BT| (S (NP (DT The) (NN mutation) (NN spectrum) (JJ H-ras) (NN codon)) (NP (CD 61) (NN mutation)) (VP (VBD showed) (NP (NP (JJ significant) (NN decrease) (NN AAA) (NN increase) (NN CTA) (NN mutation) (JJ dichloroacetic) (NN acid)) (: -) (S (NP (JJ trichloroethylene-induced) (NN tumor)) (VP (VBN compared) (NP (JJ combined) (NN control))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 179:D01.248.497.300.459.700 335:D13.444.735.544.355 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939|ES| 7:1 19:1 34:1 40:1 50:1 132:1 135:1 164:1 289:1 295:1 691:1 1119:1 2249:1 4273:1 4336:1 5475:1 5533:1 5541:1 5542:1 5543:1
1 	|BT| (S (NP (NP (DT The) (NN result) (NN show) (NN PhIP)) (NP (NP (ADJP (RB extremely) (JJ toxic)) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-)) (NP (NN mouse)) (, ,))) (ADVP (RB even)) (VP (VBZ dos) (NP (RB 10-fold) (JJR lower) (VBN tolerated) (JJ wild-type) (NN C57BL/6) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 593:B01.050.050.199.520.520.420|ES| 2:1 8:1 10:1 14:1 19:1 45:1 52:1 101:1 117:1 429:1 691:1 1533:1 2192:1 2641:1 2653:1 5416:1 5544:1 5545:1 5546:1 5547:1
1 	|BT| (S (NP (EX There)) (ADVP (RB also)) (NP (NP (JJR higher) (NN incidence) (NN K-ras) (NN activation)) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (-RRB- -RRB-))) (NP (JJ tetrachloroethylene-induced) (NN tumor)) (VP (ADVP (RB chemically)) (VBN induced) (NP (NN control) (NN tumor)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 434:E05.318.308.985.525.375 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 170:1 225:1 289:1 369:1 412:1 1121:1 1511:1 1532:1 2581:1 3217:1 4338:1
1 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1
1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NP (NN exposure) (JJ dichloroacetic) (NN acid)) (, ,) (NP (NN trichloroethylene) (NN tetrachloroethylene))) (VP (VBZ provides) (S (NP (JJ selective) (NN growth) (NN advantage)) (ADVP (RB spontaneously)) (VP (VBG occurring) (NP (NP (NN mutation) (NN codon) (CD 61) (NNS H-ras)) (, ,) (NP (NN time)) (, ,) (NP (NP (JJ responsible) (JJ small) (NN number) (JJ unique) (JJ molecular) (NN lesion)) (VP (JJ suggestive) (NP (CC either) (NP (JJ random) (JJ genotoxic) (NN mode) (NN action) (JJ non-specific) (NN result) (JJ secondary) (NN DNA) (NN damage)))))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249 113:C04.697.650 179:D01.248.497.300.459.700 322:G01.910 335:D13.444.735.544.355 526:G05.355.180 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939 1236:D02.455.526.439.880 1503:E05.318.780.700|ES| 2:1 19:1 34:1 39:1 101:1 102:1 161:1 646:1 666:1 750:1 792:1 796:1 815:1 927:1 1081:1 1119:1 1131:1 1275:1 1469:1 1506:1 1737:1 1749:1 1848:1 1953:1 2013:1 2132:1 3329:1 4273:1 4419:1 5475:1 5476:1 5477:1 5533:1 5548:1 5549:1 5550:1 5551:1 5552:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (, ,) (NP (NP (ADVP (RB together)) (NP (NNP National) (NNP Toxicology) (NNP Program) (NN study)) (VP (VBG showing) (NP (NN evidence) (NN cytotoxicity) (NN genotoxicity) (NN oxazepam)))) (, ,) (S (VP (VBP suggest) (SBAR (S (NP (NN oxazepam)) (ADVP (RB preferentially)) (VP (VBZ promotes) (NP (NN cell) (VBG activating) (NN lesion) (NN ra)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 13:D01.339.387 41:A11 946:D27.888.569.213 1265:H01.158.891 1329:D03.438.079.080.070.663|ES| 2:1 19:1 38:1 94:1 101:1 131:1 298:1 792:1 796:1 1115:1 1131:1 1538:1 1958:1 2201:1 3317:1 3336:1 4491:1 4492:1 4493:1 4741:1 4819:1
1 	|BT| (S (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (JJ important) (NN target) (NN 5-fluorouracil) (-LRB- -LRB-) (NN 5FU) (-RRB- -RRB-) (: -)) (VP (VBN based) (NP (NN therapy)))) |ET| |BS|52:E02 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 19:1 66:1 130:1 160:1 509:1 902:1 2307:1 2895:1 3081:1 5493:1
1 	|BT| (S (NP (NNS Tumors)) (VP (VBD isolated) (SBAR (S (NP (NP (NNS trout)) (VP (VBN treated) (NP (NP (NN DHEA)) (ADVP (RB alone))))) (VP (VBD contained) (NP (NP (NP (NN mutation) (NN Ki-ras)) (, ,) (NP (ADVP (RB primarily)) (NN codon) (CD 12) (-LRB- -LSB-) (CD 1) (-RRB- -RSB-) (NN G))) (: --) (NP (NP (JJR >) (DT A) (NN transition)) (, ,) (S (VP (VBG providing) (ADVP (JJ first)) (SBAR (S (NP (JJ suggestive) (NN evidence) (NN DHEA)) (VP (MD could) (NP (JJ genotoxic) (NN carcinogen)))))))))))))) |ET| |BS|8:C04 18:G05.365.590 52:E02 279:D27.888.569.100 335:D13.444.735.544.355 740:D04.808.054.079.429.625 1504:B01.050.150.900.493.817.750.825|ES| 2:1 19:1 34:1 38:1 53:1 69:1 98:1 241:1 552:1 816:1 908:1 1099:1 1119:1 1120:1 1373:1 1378:1 1466:1 1653:1 1970:1 2123:1 2125:1 2633:1 3025:1 3329:1 3720:1 4880:1 5549:1 5553:1 5554:1
1 	|BT| (S (NP (NN UDCA)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN protein) (NN mRNA) (NN level)) (NP (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 7:D12.776 8:C04 111:D13.444.735.544 122:C14.280.383 737:D04.808.105.225.272.962|ES| 4:1 7:1 19:1 62:1 118:1 124:1 249:1 325:1 365:1 399:1 1775:1 2631:1
1 	|BT| (S (S (S (VP (VBG Using) (NP (JJ genetic) (NN engineering)))) (, ,) (NP (VBN deleted) (NP (NP (JJ short) (JJ tandem) (NN repeat)) (PRN (-LRB- -LRB-) (NP (CD two) (NN repeat)) (-RRB- -RRB-))) (NN allele)) (VP (VBD retained) (S (NP (JJ long) (PRN (-LRB- -LRB-) (NP (CD three) (NN repeat)) (-RRB- -RRB-)) (NN allele)) (VP (VBP produce) (NP (JJ artificial) (NN LOH) (NN TS) (NN gene))))) (: ;)) (S (NN TS) (-LRB- -LRB-) (NP (CC +) (: /) (: -) (-RRB- -RRB-) (NN line)) (VP (VBD reduced) (NP (NP (NN TS) (NN protein) (NN expression) (JJ hypersensitive) (NN 5FU) (NN 5-fluoro-2)) ('' ') (: -) (ADVP (FW deoxyuridine) (FW vitro))) (NP (VBN compared) (JJ syngeneic) (NN control) (NN line))))) |ET| |BS|7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 394:G02.111.570.080.708.800.500 560:D03.383.742.698.875.404 1505:G05.360.340.024.340.465 1506:E05.393.420|ES| 2:1 4:1 9:1 10:1 14:1 19:1 44:1 50:1 115:1 216:1 217:1 230:1 264:1 289:1 452:1 482:1 509:1 812:1 864:1 933:1 1001:1 1004:1 1565:1 1577:1 1719:1 2325:1 5493:1 5555:1 5556:1 5557:1 5558:1 5559:1 5560:1 5561:1
1 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (SBAR (S (NP (NP (NN matrilysin) (NN expression) (JJ benign) (JJ intestinal) (NP (NN tumor) (NN mouse) (JJ heterozygous) (NN ApcMin) (NN allele))) (PRN (-LRB- -LRB-) (NP (NN Min)) (: /) (NP (CC +)) (-RRB- -RRB-))) (VP (VBD found) (SBAR (S (NP (NN mRNA)) (VP (VBD induced) (NP (NP (NP (NN majority)) (PRN (-LRB- -LRB-) (NP (CD 88) (NN %)) (-RRB- -RRB-))) (NN adenoma)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 47:A03.556.124 77:G05.360.340.024.340.030 111:D13.444.735.544 157:G05.380.383 381:C04 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 10:1 14:1 19:1 37:1 42:1 52:1 109:1 115:1 198:1 230:1 325:1 369:1 412:1 705:1 786:1 843:1 1168:1 1194:1 1288:1 3289:1 5562:1
1 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (JJ tumor-promoting) (NN change) (JJ gestational) (JJ arsenic) (NN exposure) (NN focus) (NN Ha-ras) (NN mutation) (NN gene) (NN expression) (NN change)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 155:G05.355.310 216:Z01.107.084.900.425 1158:D01.268.513.249 1266:G08.686.785.760.769|ES| 9:1 19:1 34:1 115:1 200:1 499:1 747:1 843:1 1431:1 1953:1 3776:1 3976:1 4106:1
1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NP (NN miR-122)) (VP (VBD suppressed) (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (-LRB- -LRB-) (NN IGF-1R) (-RRB- -RRB-) (NN translation)) (VP (VBD sustained) (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity))))))))) |ET| |BS|145:G02.111.087.675.871 518:D08.811.913.696.620.682.725.400.185 809:L01.178.682.920|ES| 10:1 14:1 19:1 66:1 92:1 98:1 102:1 185:1 186:1 307:1 399:1 473:1 843:1 1175:1 1789:1 1847:1 1972:1 2093:1 3652:1 3653:1 5563:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN miR-221) (NN reduction)) (VP (VBD resulted) (NP (NN alteration) (JJ EMT-associated) (NN gene) (NN E-cadherin) (NN vimentin)) (NP (RB well) (ADJP (RB significantly) (JJR slower)) (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)))) |ET| |BS|8:C04 18:G05.365.590 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 820:D12.776.395.550.200.200 1527:D05.750.078.593.900|ES| 2:1 7:1 9:1 19:1 52:1 102:1 124:1 140:1 265:1 266:1 370:1 594:1 622:1 787:1 951:1 2267:1 5687:1 5688:1 5689:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN silencing) (NN IGFBP1) (NN gene)) (VP (VBD blunted) (NP (JJ emodin-induced) (NN inhibition) (NN cell) (NN growth) (NN cell) (NN cycle) (NN arrest)))) |ET| |BS|41:A11 42:G05.355.315.203.374 43:F01.145.544 45:G07.700.320.249 773:G04.299.134.109 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 94:1 100:1 102:1 103:1 601:1 602:1 622:1 5201:1 5613:1 5690:1
-1 	|BT| (S (NP (JJ Natural) (JJ lipophilic) (NNS polyphenols)) (VP (JJ long-chain) (NP (NP (JJ polyunsaturated) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNS PUFAs)) (-RRB- -RRB-))) (SBAR (S (ADVP (RB generally)) (VBP suppress) (NN Wnt) (: -) (NN NF-kappaB) (: -) (-LRB- -LRB-) (NP (JJ nuclear) (NN factor-kappa) (NN light-chain) (NN enhancer)) (VP (VP (VBD activated) (NP (NN B-cell))) (-RRB- -RRB-) (NP (JJ related) (NN pathway))))))) |ET| |BS|41:A11 56:D02.455.426.559.389.657.715 210:D12.776.260.600 425:G01.358.500.505.650 1528:D10.251.355|ES| 10:1 14:1 19:1 154:1 163:1 383:1 419:1 972:1 1256:1 1275:1 2070:1 2199:1 2441:1 2780:1 3364:1 4674:1 5265:1 5691:1 5692:1 5693:1 5694:1 5695:1 5696:1
-1 	|BT| (NP (NP (NP (JJ Oral) (NN administration)) (SBAR (S (NP (NP (CD 50) (NN mg/kg) (NN CX-5461)) (VP (VBD induced) (NP (NN TP53) (NN expression) (NN activity)))) (VP (VBD reduced) (NP (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN MKI67)) (-RRB- -RRB-))) (NN invasion)) (PRN (-LRB- -LRB-) (NP (NN loss) (JJ ductal) (NN actin)) (-RRB- -RRB-))) (NN Hi-MYC) (NN tumor))))) (, ,) (NP (NP (NN PTEN-null)) (PRN (-LRB- -LRB-) (JJ low) (NN MYC) (-RRB- -RRB-))) (NP (NN tumor)))) |ET| |BS|8:C04 739:E02.319.267.100 1025:Z01.252.100.450 1026:Z01.252.474.651 1529:C16.131.831.512.400.410 1530:Z01.107.567.875.580.375 1531:D12.776.660.625.500 1532:D05.750.078.730.250|ES| 2:1 7:1 10:1 14:1 19:1 32:1 115:1 299:1 368:1 399:1 412:1 452:1 472:1 531:1 620:1 1018:1 2575:1 3585:1 5071:1 5697:1 5698:1 5699:1 5700:1 5701:1 5702:1
-1 	|BT| (S (NP (NP (JJ Other) (NN study)) (, ,) (ADVP (RB therefore)) (, ,)) (VP (VBN performed) (NP (NN SW480) (NN cell) (NN silibinin)) (SBAR (S (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ beta-catenin-dependent) (NN T-cell) (NN factor-4)) (PRN (-LRB- -LRB-) (NP (NN TCF-4)) (-RRB- -RRB-))) (JJ transcriptional) (NN activity) (NN protein) (NN expression) (NN beta-catenin) (NN target) (NN gene) (NN c-Myc) (NN cyclin) (NN D1))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100 1533:D12.776.260.730.875 1534:C10.597.350.400 1535:D12.776.220.145|ES| 2:1 4:1 9:1 10:1 14:1 19:1 60:1 94:1 115:1 124:1 131:1 160:1 202:1 218:1 399:1 458:1 559:1 743:1 744:1 824:1 2635:1 3096:1 5210:1 5375:1 5703:1 5704:1 5705:1
-1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (NP (NP (JJ chemoprotective) (NN effect) (NN isorhamnetin) (NN colon) (NN cancer)) (VP (VBN linked) (NP (NP (JJ anti-inflammatory) (NN activity) (NN inhibition) (JJ oncogenic) (NN Src) (NN activity) (JJ consequential) (NN loss)) (VP (JJ nuclear) (NP (NP (NN beta-catenin)) (, ,) (NP (NN activity)) (NP (JJ dependent) (NN CSK) (NN expression))))))))) |ET| |BS|23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158|ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1
-1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (S (NP (NNP ADN) (NN time)) (NP (ADVP (RB dependently)) (NP (VBD stimulated) (NP (NN WIF1) (NN gene) (NN protein) (NN expression) (NN MDA-MB-231) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 41:A11 322:G01.910 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 763:Z01.542.248.540|ES| 4:1 9:1 19:1 94:1 101:1 115:1 132:1 658:1 1081:1 2689:1 4854:1 5706:1 5707:1 5708:1
-1 	|BT| (S (NP (NN Overexpression) (NN PinX1)) (VP (VBD resulted) (SBAR (S (NP (NP (NN G1/S) (NN phase) (NN arrest) (NN cell) (NN growth/proliferation) (NN inhibition)) (, ,) (NP (NN silencing) (NN PinX1))) (VP (VBD led) (NP (NP (NN acceleration) (NN G1/S) (NN transition)) (, ,) (NP (NP (NN cell) (NN growth/proliferation) (NN promotion)) (VP (VBG inhibiting/enhancing) (NP (NN telomerase) (NN activity)) (PP (IN via) (NP (NN p16/cyclin) (NN D1) (NN pathway))))))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 86:D01.268.556.435 122:C14.280.383 183:G04.299.233.750 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 1404:G02.111.087.222.880 1536:D08.811.913.696.445.308.300.750.750 1537:G01.595.560.107|ES| 2:1 19:1 94:1 100:1 103:1 383:1 399:1 552:1 594:1 596:1 602:1 668:1 744:1 2228:1 2337:1 2529:1 4430:1 5709:1 5710:1 5711:1 5712:1 5713:1 5714:1
-1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
-1 	|BT| (S (NP (NN PinX1)) (VP (VBZ suppresses) (NP (NN bladder) (JJ urothelial) (NN carcinoma) (NN cell) (NN proliferation)) (PP (IN via) (NP (NN inhibition) (NN telomerase) (NN activity) (NN p16/cyclin) (NN D1) (NN pathway))))) |ET| |BS|43:F01.145.544 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 317:C04.557.470.200.430 933:A05.810.890 1536:D08.811.913.696.445.308.300.750.750|ES| 19:1 94:1 103:1 299:1 304:1 383:1 399:1 564:1 596:1 686:1 744:1 1078:1 5709:1 5713:1 5714:1
-1 	|BT| (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (JJ pancreatic) (NN tumor) (NN cell)) (NP (NP (VBN reduced) (NN growth) (NN xenograft) (NN tumor) (NN mouse)) (, ,) (NP (NN administration) (NN DRD2) (NN inhibitor) (NN haloperidol) (NN mouse) (JJ orthotopic) (NN xenograft) (NN tumor))) (NP (VBD reduced) (JJ final) (NN tumor) (NN size) (NN metastasis))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 113:C04.697.650 156:G05.355.315.203.374.790 362:D12.776.543.750.069.300.400.500 1069:D02.522.352.506 1538:C04.588.274.761|ES| 2:1 7:1 19:1 52:1 94:1 102:1 265:1 380:1 452:1 464:1 467:1 515:1 516:1 806:1 1210:1 2142:1 2575:1 3744:1 3884:1 5283:1
-1 	|BT| (NP (NP (ADVP (RB Similarly)) (, ,) (NP (NP (NN HT-29) (NN colon) (NN cancer) (NN cell)) (, ,) (NP (NN isorhamnetin)) (VP (VP (VBD inhibited) (S (NP (JJ oncogenic) (NN Src) (NN activity) (NN beta-catenin) (JJ nuclear) (NN translocation)) (VP (VBG inducing) (NP (NN expression) (NN csk))))) (, ,) (NP (VBN verified) (NN RNA) (NN interference) (NN knockdown) (NN csk)))))) |ET| |BS|23:D12.776.091.249 122:C14.280.383 156:G05.355.315.203.374.790 279:D27.888.569.100 463:C23.550.210.870 792:A11.251.210.190.475|ES| 2:1 18:1 19:1 60:1 94:1 113:1 115:1 365:1 399:1 464:1 515:1 516:1 726:1 953:1 1256:1 1618:1 1864:1 2782:1 3673:1 3674:1 5715:1 5716:1
-1 	|BT| (S (NP (NNP Simvastatin)) (VP (VP (VBD decreased) (NP (NN Skp2) (NN expression) (JJ transcriptional) (NN level))) (, ,) (VP (VBD resulted) (S (NP (NN p27) (NN accumulation)) (VP (VBG preventing) (NP (JJ proteasomal) (NN degradation))))) (, ,) (NP (NN effect) (VP (VBD mediated) (NP (NP (NP (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NN inhibition)))))) |ET| |BS|43:F01.145.544 209:G02.111.087.847 250:E07.305.812 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900 1281:D05.500.562.500 1293:G03.495|ES| 2:1 10:1 14:1 19:1 75:1 103:1 115:1 202:1 249:1 251:1 437:1 487:1 559:1 594:1 597:1 859:1 860:1 861:1 862:1 1124:1 1785:1 1937:1 2120:1 2961:1 4556:1
-1 	|BT| (NP (NP (ADVP (RB Specifically)) (, ,) (NP (NP (NN coregulation) (NN kinase) (NN p38) (NN ERK)) (, ,) (NP (NN translation) (NN regulator)) (NP (NN 4EBP1)) (, ,) (NP (NP (NN transcription) (NN factor) (NN CREB)) (VP (VBG proliferating) (NP (JJ normal) (NN colon) (NN cell)))) (NP (VBD lost) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 46:A03.556.124.526.356 145:G02.111.087.675.871 166:D12.776.930 469:D08.811.913.696 809:L01.178.682.920|ES| 2:1 19:1 94:1 113:1 118:1 185:1 235:1 245:1 470:1 473:1 487:1 1666:1 2042:1 2865:1 5047:1 5717:1 5718:1 5719:1 5720:1
-1 	|BT| (S (NP (NN Sulindac)) (VP (VBZ enhances) (NP (NP (JJ adenoviral) (NN vector)) (VP (VBG expressing) (NP (NP (NN mda-7)) (: /) (NP (NP (JJ IL-24-mediated) (NN apoptosis)) (NP (JJ human) (NN lung) (NN cancer)))))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 123:G05.360.337 251:D02.455.426.559.847.486.875 542:B04.280.030|ES| 18:1 19:1 36:1 89:1 328:1 362:1 810:1 1356:1 2965:1 5721:1 5722:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN administration) (NN SHH) (NN inhibitor)) (VP (MD could) (NP (NP (JJ effective) (NN strategy) (VBP prevent) (JJ colitis-induced) (JJ colorectal) (NN carcinogenesis)) (, ,) (VP (ADVP (RB mainly)) (VBG targeting) (NP (NP (NN IL-6)) (NN signaling))) (, ,) (NP (VBG ablating) (NNS CSCs)) (, ,) (S (VP (VBG suppressing) (NP (NP (JJ oncogenic) (NN inflammation)) (, ,) (S (VP (VBG achieving) (NP (NN chemoquiescence)) (ADVP (RB ultimately))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 69:G02.111.087.800 201:D12.644.276.374.465.224 279:D27.888.569.100 525:C23.550.470 556:C11.768.175|ES| 2:1 17:1 19:1 195:1 207:1 380:1 616:1 733:1 793:1 796:1 908:1 953:1 1114:1 1537:1 1538:1 1639:1 1966:1 2250:1 2575:1 3064:1 3148:1 5488:1 5664:1 5723:1 5724:1 5725:1 5726:1 5727:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)) (, ,) (S (VP (VBG finding) (NP (JJ demonstrative) (NN existence) (JJ novel) (NN pathway) (NN simvastatin)))))) (VP (VBZ induces) (NP (NP (NN G0/G1) (NN arrest)) (VP (VBG upregulating) (NP (NP (NN p21) (NN p27) (VBG activating) (NNP AMPK)) (VP (VBG inhibiting) (NP (NN STAT3-Skp2) (NN axis)))) (, ,) (ADVP (RB respectively)))))) |ET| |BS|82:D12.644.360.024.342.300 122:C14.280.383 259:D12.776.395.240.150.500 507:D12.776.157.743 579:A02.835.232.834.151.383 754:D02.455.426.559.847.638.400.900|ES| 2:1 19:1 214:1 371:1 383:1 602:1 880:1 891:1 927:1 1124:1 1135:1 1537:1 1538:1 1958:1 2089:1 2679:1 3140:1 4692:1 5666:1 5728:1 5729:1 5730:1
-1 	|BT| (NP (NP (NP (DT The) (NN colon) (JJ epithelial) (NN cell) (NN line)) (NP (NP (NN NCM460) (NN colon) (NN cancer) (NN cell) (NN line) (NN HT-29) (NN Caco-2)) (VP (VBN exposed) (NP (NN P) (NN anaerobius) (NN control) (NNS bacteria))))) (: ;) (NP (NN cell) (VBN analyzed) (NP (NN immunoblot)) (, ,) (NP (NN proliferation)) (, ,) (NP (NP (JJ bacterial) (NN attachment) (NN analysis)) (VBN compared) (NN gene) (NN expression) (VBG profiling) (NN study)))) |ET| |BS|41:A11 46:A03.556.124.526.356 94:A11.251.210 718:E05.588.570 792:A11.251.210.190.475 802:E05.478.566.320 1286:E05.393.332 1539:B03|ES| 2:1 9:1 18:1 19:1 50:1 94:1 113:1 115:1 127:1 131:1 217:1 264:1 289:1 299:1 311:1 661:1 691:1 1168:1 2148:1 2782:1 2830:1 3102:1 3355:1 5731:1 5732:1 5733:1 5734:1 5735:1
-1 	|BT| (S (NP (DT The) (JJ limonoid-treated) (NN xenograft)) (VP (VP (VBD exhibited) (NP (NP (JJ significant) (NN downregulation) (NN expression) (NN protein)) (VP (VBN involved) (NP (NP (NP (NN tumor) (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN c-IAP-1)) (, ,) (NP (NN survivin)) (, ,) (NP (NN Mcl-1))) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN c-Myc) (NN cyclin) (NN D1)) (-RRB- -RRB-))) (, ,) (NP (NN invasion) (-LRB- -LRB-) (NN MMP-9) (, ,) (NN ICAM-1))))) (-RRB- -RRB-)) (, ,) (NP (NP (NN metastasis) (-LRB- -LRB-) (NN CXCR4) (-RRB- -RRB-)) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))))) |ET| |BS|7:D12.776 8:C04 52:E02 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 108:G04.299.316 113:C04.697.650 175:J01.897.280.500.269 215:D12.644.360.262.150.100 586:D08.811.277.656.300.480.205.360 1204:D12.776.543.750.100.160.500.400 1325:D12.776.395.550.200.450|ES| 2:1 4:1 7:1 10:1 14:1 19:1 94:1 115:1 135:1 158:1 265:1 274:1 299:1 595:1 609:1 620:1 691:1 743:1 744:1 774:1 806:1 824:1 2066:1 2158:1 2229:1 2502:1 4220:1 4732:1 4814:1 5312:1 5736:1 5737:1
-1 	|BT| (S (PP (DT These) (S (VP (VBG finding) (S (VP (VBP demonstrate) (NP (NN miR-137) (JJ crucial) (NN regulator) (NN cancer) (NN response) (NN doxorubicin) (NN treatment))))))) (, ,) (VP (VBP identify) (S (NP (NN miR-137) (ADJP (RB highly) (JJ promising)) (NN target)) (VP (VB reduce) (NP (JJ CAR-driven) (NN doxorubicin) (NN resistance)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 66:F01.658.293 136:D02.455.426.559.847.562.050.200.175 139:J01.937.500.100|ES| 2:1 18:1 19:1 160:1 235:1 420:1 494:1 502:1 546:1 599:1 626:1 792:1 832:1 927:1 1094:1 1517:1 2361:1 3690:1 5738:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (S (VP (VBG signaling) (NP (NN cascade) (, ,) (JJ positive) (ADJP (NN feedback) (NN loop) (JJ cooperative)) (NN interplay) (NN transcription) (JJ factors-induced) (NN expression) (NN IGFBP1) (NN gene)))) (VP (VBP contribute) (NP (JJ overall) (NN response) (NN emodin)))) |ET| |BS|69:G02.111.087.800 83:L01.143.283.425 155:G05.355.310 166:D12.776.930 696:V02.270.500 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 115:1 195:1 233:1 247:1 248:1 450:1 487:1 494:1 1691:1 2510:1 5274:1 5613:1 5739:1 5740:1 5741:1 5742:1
-1 	|BT| (S (S (VP (TO To) (VP (VB confirm) (S (VP (VBG sensitizing) (NP (NN effect) (NN NAC1) (NN inhibition) (NN cytotoxicity) (NN cisplatin))))))) (VP (VBD attributed) (NP (NN suppression) (NN autophagy)) (, ,) (NP (NP (VBN assessed) (NN effect) (NN autophagy) (NN inhibitor) (NN 3-methyladenosine) (NN chloroquine)) (, ,) (NP (NP (NP (JJ small) (VBG interfering) (NNS RNAs)) (PRN (-LRB- -LRB-) (NP (NNS siRNAs)) (-RRB- -RRB-))) (VP (VBG targeting) (NP (NN beclin) (CD 1) (NN Atg5) (NN cytotoxicity) (NN cisplatin))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 117:D13.150.650.700 390:G04.299.139.399 498:D01.210.375 946:D27.888.569.213 961:D03.438.810.050.180|ES| 2:1 10:1 14:1 19:1 75:1 98:1 103:1 380:1 616:1 750:1 828:1 1317:1 1761:1 2137:1 2453:1 3019:1 3044:1 3317:1 3378:1 3531:1 3823:1 5743:1 5744:1 5745:1 5746:1 5747:1 5748:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ similar) (NN result) (JJ cellular) (NN model)) (JJ hepatocellular) (NN colon) (NN cancer)) (, ,) (S (VP (VBG indicating) (S (NP (JJ doxorubicin-sensitizing) (NN effect) (NN miR-137) (NN tumor)) (ADJP (JJ type-specific))))))) |ET| |BS|8:C04 41:A11 136:D02.455.426.559.847.562.050.200.175|ES| 2:1 7:1 18:1 19:1 72:1 75:1 101:1 113:1 261:1 303:1 332:1 420:1 843:1 2236:1 3074:1 5749:1 5750:1
